Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy

Clinical Immunology(2020)10.1016/j.clim.2020.108598Source: DataRank Database

Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy is a research paper published in Clinical Immunology (2020). On theSindex it has a DataRank of 0.838. It has been cited 265 times.

N/A

0.838DataRank · unranked

Scored on demand from live citation data

Open Access265 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 5.02)OA: greenTopics (99)Linked Datasets (24)DataCite Reuse (24)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.838

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (23)

Bruno G. P. Pires da Silva,Benedito Antônio Lopes da Fonseca ORCID,Natasha Peixoto Fonseca ORCID,Maria Auxiliadora‐Martins ORCID,Sara Mastaglio ORCID

Live enrichment

PubMed:32961333 PMC:PMC7501834 OpenAlex:https://openalex.org/W3087090615

Fundação de Amparo à Pesquisa do Estado de São Paulo

Grant: 13/08135-2

National Institutes of Health

Grant: P01AI068730

National Institutes of Health

Grant: 5P01AI068730-07

A complement therapeutics toolbox for tailored & targeted immunomodulation

Novartis

Viropharma

Alexion Pharmaceuticals

FWCI

5.02

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: other-oa

repositoryhttps://hdl.handle.net/2108/260896

publisherhttps://api.elsevier.com/content/article/PII:S1521661620307580?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1521661620307580?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clim.2020.108598

Fields of Study

COVID-19 Clinical Research StudiesComplement system in diseasesSARS-CoV-2 and COVID-19 Research0301 basic medicine0302 clinical medicine03 medical and health sciences

MeSH Terms

BetacoronavirusCOVID-19SARS-CoV-2C-Reactive ProteinComplement ActivationComplement C3Complement C5FemaleHumansImmunologic FactorsMaleMiddle AgedNeutrophilsPeptides, CyclicPneumonia, ViralRespiratory Distress SyndromeSeverity of Illness IndexCohort StudiesBiomarkersInterleukin-6Gene ExpressionCoronavirus InfectionsComplement Inactivating AgentsPandemicsAntibodies, Monoclonal, HumanizedExtracellular Traps

Keywords

EculizumabImmunologyComplement systemComplement component 5ARDSMedicineInflammationThrombotic microangiopathyBlockadeNeutrophil extracellular trapsAntibodyLungInternal medicineReceptorBiomarkersDrug EfficacyThromboinflammationAmy-101C5 BlockadeCovid-19C3 InhibitionMaleNeutrophilsGene ExpressionSettore MED/01 - STATISTICA MEDICASeverity of Illness IndexExtracellular TrapsCohort StudiesImmunologic FactorMonoclonalImmunology and AllergyViralHumanizedComplement ActivationCyclicRespiratory Distress SyndromeComplement C5amy-101; biomarkers; c3 inhibition; c5 blockade; covid-19; drug efficacy; eculizumab; thromboinflammation; antibodies; monoclonal; humanized; betacoronavirus; c-reactive protein; cohort studies; complement activation; complement c3; complement c5; complement inactivating agents; coronavirus infections; extracellular traps; humans; interleukin-6; gene expression; immunologic factors; middle aged; pandemics; peptides; cyclic; pneumonia; viral; respiratory distress syndrome; sars-cov-2; severity of illness indexComplement C3Middle AgedExtracellular TrapC-Reactive ProteinFemaleCoronavirus InfectionsHumanAMY-101; Biomarkers; C3 inhibition; C5 blockade; COVID-19; Drug efficacy; Eculizumab; Thromboinflammation; Antibodies, Monoclonal, Humanized; Betacoronavirus; Biomarkers; C-Reactive Protein; Cohort Studies; Complement Activation; Complement C3; Complement C5; Complement Inactivating Agents; Coronavirus Infections; Extracellular Traps; Humans; Interleukin-6; Gene Expression; Immunologic Factors; Middle Aged; Pandemics; Peptides, Cyclic; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Severity of Illness IndexAntibodies, Monoclonal, HumanizedAntibodiesArticleBetacoronavirusAMY-101; Biomarkers; C3 inhibition; C5 blockade; COVID-19; Drug efficacy; Eculizumab; Thromboinflammation; Antibodies, Monoclonal, Humanized; Betacoronavirus; Biomarkers; C-Reactive Protein; COVID-19; Cohort Studies; Complement Activation; Complement C3; Complement C5; Complement Inactivating Agents; Coronavirus Infections; Extracellular Traps; Female; Gene Expression; Humans; Immunologic Factors; Interleukin-6; Male; Middle Aged; Neutrophils; Pandemics; Peptides, Cyclic; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Severity of Illness Index616HumansImmunologic FactorsPandemicsBetacoronaviruPandemicCoronavirus InfectionSARS-CoV-2Interleukin-6Settore MED/09 - MEDICINA INTERNABiomarkerPneumoniaComplement Inactivating AgentComplement Inactivating AgentsCohort StudiePeptides

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients

10.6084/m9.figshare.13787143.v1figshare

Additional file 1 of Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients

10.6084/m9.figshare.13787143figshare

Additional file 2 of Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients

10.6084/m9.figshare.13787146.v1figshare

Additional file 2 of Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients

10.6084/m9.figshare.13787146figshare

Additional file 3 of Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients

10.6084/m9.figshare.13787149.v1figshare

Additional file 3 of Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients

10.6084/m9.figshare.13787149figshare

Additional file 4 of Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients

10.6084/m9.figshare.13787155.v1figshare

Additional file 4 of Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients

10.6084/m9.figshare.13787155figshare

Additional file 5 of Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients

10.6084/m9.figshare.13787158.v1figshare

Additional file 5 of Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients

10.6084/m9.figshare.13787158figshare

Additional file 1 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462377.v1figshare

Additional file 1 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462377figshare

Additional file 2 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462380.v1figshare

Additional file 2 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462380figshare

Additional file 3 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462386.v1figshare

Additional file 3 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462386figshare

Additional file 4 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462389.v1figshare

Additional file 4 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462389figshare

Additional file 5 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462392.v1figshare

Additional file 5 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462392figshare